New T-cell services to support your cancer research and development of cancer immunotherapies We offer to validate T-cell antigenicity of cancer neoepitopes to find the best peptide candidate for your cancer vaccine strategy and monitor the success of cancer vaccine trials via enzyme-linked immune absorbent spot (ELISpot) assay. Moreover, we provide T-cell receptor (TCR) sequencing to analyze the TCR repertoire, or single-cell approaches to unveil antigen-specific TCRs for your biomarker and immunotherapy research. 1 Identification neoepitope candidates 2 Prediction of HLA binding & synthesis of peptides 3 Validation of T-cell immunogenicity Antigen-specific per well 4 Isolation of epitope specific T-cells & sequencing of their receptors •H Parean JJJ BiotechnoJogijes Antigen-specific cell sorting via Dextramer® technology Exemplary workflow 1. Tumor-specific neoantigens and shared/common neoantigens are identified via genome analyses of tumor tissue versus healthy tissue. 2. Identified neoantigens are validated for HLA-binding/antigenicity via prediction models and promising peptide candidates are synthesized. 3. Peptides are applied in ELISpot or FluoroSpot assays in patient-derived PBMC culture. Immunogenic peptides are identified. 4. Antigen-specific T-cells are isolated, alpha and beta chains of T-cell receptors are analyzed via NGS. PEPperPRINT GmbH • +49 6221 7264489 • pepperprint.com • in pepperprint-gmbh sf@pepperchip f PEPperPRINTgmbh OPEPperPRINT

Tumor-specific neoantigens and shared/common neoantigens are promising targets for cancer vaccination strategies. In both cases, the development of neoantigen-based cancer vaccines starts with identifying mutations by comparing the tumor genome to normal tissues. At PEPperPRINT, we offer the essential step of validating T-cell dependent immunogenicity of identified peptide neoantigens. We can monitor the efficacy of vaccination approaches by assessing antigen-specific T-cell responses via ELISpot assay in PBMC culture. This T-cell service can be combined with an anti-tumor antibody response analysis...